Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Clinical trial NCT02576990 · COMPLETED
Trial details
- NCT number
- NCT02576990
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-02
- Primary completion
- 2019-05-28
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.